2024-2025 COVID-19 Vaccine Shows No Increased Safety Risk
A study of nearly 90,000 insured adults confirms the vaccine's safety profile and effectiveness in preventing mortality.
Updated on Oct. 27, 2026 in COVID-19

Live Poll
Do you trust the safety profiles of the latest variant-adapted COVID-19 vaccines?
A 2026 safety study found no increased risk of 20 pre-specified adverse events among 89,485 individuals who received the 2024-2025 Pfizer-BioNTech COVID-19 vaccine. These findings, based on data collected between August 2024 and March 2025, offer updated safety profiles for those considering the vaccine.
Why it matters
Understanding the safety and mortality-reduction profile of updated vaccines helps individuals manage their health decisions during seasonal respiratory virus surges. This research confirms that co-administration with a flu shot, common among 75.6% of participants, does not alter established safety outcomes.
A safety study using a self-controlled risk interval design evaluated 89,485 insured individuals, finding no rise in 20 pre-specified adverse events. Separately, a target trial emulation in 538,631 veteran pairs showed 65.53% effectiveness against mortality, rising to 69.77% in those 75 and older.
The players
Pfizer
A global pharmaceutical company known for developing mRNA-based vaccines and various cardiovascular and oncology therapeutics.
BioNTech
A biotechnology firm that pioneers mRNA technology for infectious disease vaccines and personalized cancer immunotherapies.
The details
Researchers employed a self-controlled risk interval design to monitor for adverse health conditions, such as cardiovascular and immune-mediated disorders, following vaccination. By comparing the incidence of these conditions during specific post-vaccination windows against control timeframes, the study isolated potential vaccine-related effects. The data reflects the broad clinical experience gained from more than 5 billion distributed doses of the mRNA-based BNT162b2 platform.
Timeline
August 2024 - March 2025: Study participants received the BNT162b2 vaccine.
2026: Publication of the safety study findings in Vaccine.
Health Landscape
This research contributes to the continuous safety monitoring framework established by the FDA for updated vaccine formulations. It positions the current mRNA platform alongside evolving efforts to develop combination shots for influenza and respiratory syncytial virus.
The findings support the safety of receiving a seasonal flu shot and a COVID-19 vaccine during the same visit. If you have questions about the relevance of these findings to your personal health history, discuss them with your physician during your next primary care appointment.
The takeaway
This analysis provides reassurance regarding the safety profile of the 2024-2025 COVID-19 vaccine for the insured adult population. Continue to track your vaccination status and discuss the appropriate timing of annual immunizations with your healthcare provider.
Further reading
For more information on vaccine guidance and safety, visit COVID-19.
More information
Review the full FDA Pfizer/BioNTech supportive data for details on the study's methodologies.
Source note: This article includes information reported by Drugtopics.
Live Poll
Do you trust the safety profiles of the latest variant-adapted COVID-19 vaccines?





